Work

A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships

Year: 2022

Type: review

Abstract: While progress has been made in fighting diseases disproportionally affecting underserved populations, unmet medical needs persist for many neglected tropical diseases. The World Health Organization has encouraged strong public-private partnerships to address this issue and several public and private organizations have set an example in the past showing a strong commitment to combat these diseases. Pharmaceutical companies are contributing in different ways to address the imbalance in research efforts. With this review, we exemplify the role of a public-private partnership in research and development by the journey of our dengue antiviral molecule that is now in early clinical development. We detail the different steps of drug development and outline the contribution of each partner to this process. Years of intensive collaboration resulted in the identification of two antiviral compounds, JNJ-A07 and JNJ-1802, the latter of which has advanced to clinical development.

Source: Antiviral Research

DOI: 10.1016/j.antiviral.2022.105495

Authors: Olivia Goethals, Natalia V. Voge, Bart Kesteleyn, Patrick Chaltin, Tim Jinks, Tine De Marez, Anil Koul, Ruxandra Draghia-Akli, Johan Neyts, Marnix Van Loock

Institutions: Janssen (Belgium), Janssen Research & Development (United States), KU Leuven, Wellcome Trust, Rega Institute for Medical Research, Global Virus Network

Language: English

Topic: Mosquito-borne diseases and control

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDGs: Good health and well-being, Partnerships for the goals

Open Access status: hybrid

Estimated APC paid: $3,290

Funders: U.S. Department of Health and Human Services, Aix-Marseille Université, University of Texas Medical Branch, Wellcome Trust, Agentschap Innoveren en Ondernemen, Universität Heidelberg, Fonds Wetenschappelijk Onderzoek, KU Leuven, Vlaamse regering, Herculesstichting, Rega Foundation, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Awards: Discovery of new drugs for the prophylaxis and treatment of dengue virus infections in humans., G1493554382, G2704148134, G4477299544, G5033194471, G5069427589, G5104309309, G5387595331, Development of small molecule directly acting non-entry inhibitors against thehuman respiratory syncytial virus, G8060332025, G8512689859, G897611082, G9000108771, G9000119263

OpenAlex ID: W4312081404

FWCI: 0.742

Cites: 25

Cited by: 18

Related to: 10